ESC 365 - Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.

Open Access

Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.

Session: Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Topic: Haemodynamics of Heart Failure

Speaker: Doctor A. Muslin (Watertown, US)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Anthony Muslin

Tectonic Therapeutic, Inc., Watertown (United States of America)

1 presentation

0 follower

6 more presentations in this session

Discussant panel

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study

Speaker: Professor S. Greene (Durham, US)

Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy

Speaker: Doctor A. Porcari (London, GB)

Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

Speaker: Professor I. Olivotto (Florence, IT)

Pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2

Speaker: Doctor J. Nunez Villota (Valencia, ES)

Access the full session

Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Speakers: Doctor A. Muslin, Professor S. Greene, Doctor A. Porcari, Professor I. Olivotto, Doctor J. Nunez Villota

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources